Low-Concentration Ergoline Autoinjector for At-Home Headache Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for migraines and cluster headaches, such as triptans and dihydroergotamine (DHE), require clinical administration, leading to delayed treatment, inconsistent absorption, and side effects, especially when self-administered, and are not effective for a significant minority of patients.

Innovation Solution

A preassembled, prefilled, single-use delivery device containing a low concentration of ergoline derivatives like dihydroergotamine, designed for self-administration outside a clinical setting, using an autoinjector with a syringe, needle, and trigger mechanism for easy and rapid treatment.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If high concentration of ergoline derivative is administered to ensure therapeutic effectiveness, then treatment efficacy is improved, but side effects increase

Engineering Contradiction:

Improvetreatment efficacyVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the concentration parameter of the ergoline derivative formulation from high to low (specifically 0.1-0.5 mg/mL), and compensates by optimizing other parameters such as delivery mechanism (autoinjector for rapid subcutaneous absorption) and formulation composition (pH adjusters, antioxidants, preservatives) to maintain stability and efficacy while reducing side effects

Inventive Principle:

Principle #35Parameter changes

2Measurement precision

If clinical administration is required to ensure proper dosing, then dosing accuracy is improved, but treatment delay increases

Engineering Contradiction:

Improvedosing accuracyVSAvoidtreatment delay

Core Design Contradiction:

Measurement precisionVSLoss of time

Solution Approach 1:

The patent prepares the medication in advance as a pre-filled, single-dose autoinjector device that is ready for immediate use at home, eliminating the need for clinical preparation and administration setup, thus providing rapid treatment while maintaining accurate dosing through pre-calibrated delivery mechanisms

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent enables patients to self-administer the medication at home using a simple autoinjector device that requires minimal training, eliminating the need for clinical staff involvement and reducing treatment delay while maintaining dosing accuracy through the device's built-in measurement and delivery control

Inventive Principle:

Principle #25Self-service

3Ease of operation

If nasal spray dosage form is used to enable self-administration, then ease of operation is improved, but absorption consistency deteriorates

Engineering Contradiction:

Improveself-administration capabilityVSAvoidabsorption consistency

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent replaces the nasal spray mechanical delivery system with an autoinjector that uses a spring-loaded or motor-driven mechanism to deliver the medication subcutaneously, providing more reliable and consistent absorption through direct injection into the bloodstream while maintaining ease of operation through simple button-press activation

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

4Measurement precision

If multiple steps are required for proper administration, then dosing accuracy is improved, but device complexity increases

Engineering Contradiction:

Improvedosing accuracyVSAvoidadministration steps

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent combines multiple functions (dosing measurement, injection delivery, needle retraction, and safety features) into a single integrated autoinjector device that performs all operations automatically through one simple user action, eliminating the need for multiple separate steps while maintaining dosing accuracy through pre-programmed delivery control

Inventive Principle:

Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables patients to administer ergoline derivatives quickly and effectively at home, reducing side effects and demand on emergency rooms, providing faster relief and improving treatment accessibility.

Implementation Method 1

acting as an agonist to the serotonin receptors and causing vasoconstriction of the intracranial blood vessels

Methodology Applied

Scientific EffectVasoconstriction:

Data Source

PatentUS12414941B2Low concentration delivery of an ergoline derivative for treatment of a headache

Publication Date: 2025.09.16 RELEVALE INC

AI summary

Provided are ergoline derivative containing medicaments disposed within a preassembled, prefilled, single-use delivery device, methods for administering a medicament using a preassembled, prefilled, single-use delivery device, and systems or kits that contain one or more preassembled, prefilled, single-use devices and user instructions, such as for treatment of a migraine or other headache.